Mobile Menu

GenBio Inc.

'Expanding Possibilities Through Nature'

Minimum target reached
Closed on 10/09/21


amount committed 


target amount 


max amount 

Regulation CF

exemption used 


pre money valuation 


min investment 



Security Type
Common Stock
$2.00 per Share


Who are we
GenBio Inc is a US-based Biotechnology company with unique expertise based on a crucial medical research breakthrough - described by the US scientific team as “never seen before”. GenBio aims to create the next generation of anti-inflammatory drugs... We intend to disrupt the $191 Billion anti-inflammatory drug market!    



Current prescription drugs are associated with significant toxicity issues that can seriously impact consumers’ health; cardiovascular and gastrointestinal side effects are common. There are also increasing worries about antimicrobial resistance. GenBio’s innovative research will address all these concerns and produce the next generation of anti-inflammatory drugs.


GenBio is developing an entirely new class of more potent, yet far less toxic anti-inflammatory drugs, based on a newly discovered and unique new class of molecules.

We are the first company in the world to identify, then research a unique rare natural extract showing truly remarkable and unique capabilities to treat a variety of ailments and diseases way more effectively and yet with way less side effects.

Many prescription drugs currently marketed for a wide variety of ailments are originally isolated from plants and/or are semi-synthetic analogs of phytochemicals. It has been estimated that approximately 25% of all prescription drugs currently in use are of plant origin. Furthermore, approximately 75% of new anticancer drugs marketed between 1981 and 2006 were derived from plant compounds; morphine and aspirin are other well-known drugs derived from plant extracts.

Our extract has undergone scientific investigation in the USA and been described as “a world first” and “never seen before”. Based on the science to hand, the Company is, in our opinion, uniquely poised to make trailblazing new discoveries for a new generation of drugs in certain classes.

Our aim is to replace some current prescription medications worldwide (along with patents) through our USA-based research program. Successful research and the resulting patenting of these molecules will create a near-monopoly of entirely new classes of pharmaceutical natural health and nutraceutical products.



Achievement & Traction

GenBio Inc seeks capital to advance its current research findings to the next critical stage with a specialized scientific team that is already briefed and in place in the USA and also backed up by another international panel of scientists specializing in this field.




Anti-Inflammatory Drugs Market to Exhibit 9.3% CAGR by 2027 Owing to Rising Prevalence of Inflammatory Health Conditions: Fortune Business Insights™


The global Anti-Inflammatory Market is expected to reach USD 191.42 billion by 2027 on account of increasing investments in the development of biologics for treating autoimmune inflammatory diseases. Anti-inflammatory drugs help to reduce inflammation in the body and treat health conditions such as arthritis, asthma, rheumatoid arthritis, sinusitis, and others.



GenBio aims to be the first company in the world to isolate and fractionate and thus identify a new molecule for a new generation of drugs initially focused to treat arthritis, all based on the remarkable scientific findings from the USA.


Business Model

The Company’s strategic objective, subject to a successful capital raise, is to proceed without delay to an IPO on the NASDAQ or NYSE. Its research program should create an ongoing suite of patents that will provide significant media releases to the market. Fifteen acquisitions of inflammatory drugs, primarily by drug companies from 2016 - 2020 at the 'discovery' phase, averaged a median total sale price of over $US 900 million per deal. Pharma companies are dependent on innovation from emerging biotech companies to develop new products. Those drug companies that don’t do deals will fall behind in the race to develop better therapeutics.


We as well expect a sale of all assets within 12-18 months at a price that reflects the uniqueness of our research into novel patented anti-inflammatory drugs. GenBio should be a compelling acquisition opportunity for a major pharmaceutical company in the inflammation and anti-infective field.




Giles Tilley,

Managing Director

Giles Tilley has over 35 years of Senior International Business Development & Management experience within the Natural Healthcare industries. Giles has worked closely with the Australian government for more than 15 years identifying innovative natural Australian healthcare products and technologies and guiding them from initial market entry strategy to international success, including working on Australian Manuka Honey in international markets, especially in Germany and Japan. 


He has gained widespread success as an innovative entrepreneur, having stunned Australia by becoming only the second person ever in its history to sell non-alcohol specialized dermaceuticals to NASA shuttle operations in the U.S., a feat which gained him both media attention and a political citation from the Queensland State Premier. He has consulted to Medifruit Pty Ltd since 2010 and driven the Company’s international R&D program, culminating recently in a platform of patents in the pain and inflammatory category.   


Since 2010 he has branched out as a specialist consultant and is retained by GenBio to advise on rare novel extracts for the U.S. market. His expertise is in start-ups and he has guided several to success in his 35-year career in this challenging area. Giles holds both a BA and MA from Oxford University.


Todd D. Sonoga, Director,

Chief Marketing Officer  

Todd has successfully represented public and private companies for over 20 years, consulting them on market awareness, support, raising capital, identifying merger and acquisition targets, advertising, marketing & branding. In 1992, Todd was recruited by Wall Street Publishing for their ‘The Small-Cap Report,’ out of Newport Beach California where he oversaw research, training, subscriber management, and served as Editor of the newsletter.  


Todd in 1998, founded Trilogy Marketing Strategies, Wall Street Microcap in 2013, and Crowdfunding Power in 2014. In early 2017, Todd co-founded and assumed the role of Chief Marketing Officer for WFN1 News Corp. (WFN1) and the show ‘CEO Money’ on Dallas Talk Radio Show on IHeart’s 1190 AM. Currently, Todd also owns and operates one of North America’s largest investor networks, with a total reach of over 10 million investors, and is a member or administrator to over 700 investment rooms, groups, boards, and affiliate investment websites.


Professor Lindsay Brown,

Chief Scientific Officer, Consultant to Board 

Professor Lindsay Brown is formerly a Professor of Biomedical Sciences at, University of Southern Queensland, Australia, and since 2015 a Fellow of the International Academy of Cardiovascular Science. His 35 years of scientific research encompasses an emphasis on drugs acting on the heart and associated blood vessels, endocrine organs, and brain.


His research team is internationally recognized for using rat models to determine whether interventions, including many natural products, can reverse or prevent disease-induced changes of the heart, liver, kidney, and adipose tissue, and to indicate whether these interventions should be further tested in humans with these diseases. His recent studies have characterized the prevention of obesity-induced osteoarthritis in rats. Further, he has reported, including National TV, the decrease in blood pressure in mildly hypertensive patients using Australian Queen Garnet plum juice. He is an editor of Nutrients and Journal of Clinical Medicine. He also holds a USQ Excellence in Research award 2015.


Use of Funds

It is vital GenBio Inc. rapidly raise $1,070,000 in capital to complete the modest first phase of our research program in California. We intend to use the funds for the isolation & fractionation of key molecules and platforms and then patent these discoveries to firmly secure the research program's intellectual property. This ongoing dynamic joint USA-Australian IND (Investigative New Drug) Program should yield enormous benefits for both investors and humanity.



Todd Sonoga
Todd Sonoga2 years ago

Dakshidin CEO Joins GenBio CEO on Stock Day Podcast to Discuss Entering 191 Billion Dollar Anti-Inflammatory Market, Their Strategic Partnership and Research Potential

 SAN FRANCISCO, CA / ACCESSWIRE / May 20, 2021 / Dakshidin Corp (OTC PINK:DKSC) CEO Chris Haigh and Giles Tilley, Managing Director of GenBio Inc. an early-stage Biotechnology Company joined Stock Day host Everett Jolly for an interview. Read Full> Press Release 5-20-2021


Load More


Unfortunately, this securities offering is closed. For questions, please email Thanks!


Start-up Valuation Download
Pitch Deck Download
Offering Statement Download

Other Disclosures

Read the Form C filed with the SEC for other important disclosures, like financial statements, Directors, Officers, shareholders with more than 20% of voting rights, and more.
Special Note Regarding Forward-Looking Statements
This offering contains forward-looking statements within the meaning of the federal securities laws. We caution investors that any forward-looking statements presented in this offering, or which management may make orally or in writing from time to time, are based on the Company’s beliefs and assumptions made by, and information currently available to, the Company. When used, the words “anticipate,” “believe,” “expect,” “intend,” “may,” “might,” “plan,” “estimate,” “project,” “should,” “will,” “would,” “result” and similar expressions, which do not relate solely to historical matters, are intended to identify forward-looking statements. Such statements are subject to risks, uncertainties and assumptions and are not guarantees of future performance, which may be affected by known and unknown risks, trends, uncertainties and factors that are beyond the Company’s control. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, estimated or projected. While forward-looking statements reflect the Company’s good faith belief when made, they are not guarantees of future performance. The Company expressly disclaims any responsibility to update forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Moreover, we operate in a very competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this offering may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. We undertake no obligation to revise or publically release the results of any revision to these forward-looking statements, except as required by law. Given these risks and uncertainties, prospective investors are cautioned not to place undue reliance on such forward-looking statements.

Back to top